Our new BASE Clinical facility is opening in 2024 at the Translational Research Institute (TRI).
The facility includes state-of-art GMP clean rooms and laboratories and will support the production and analysis of mRNA/LNP batches for clinical trials.
BASE Clinical will provide the process development, scalability, production and quality needed to progress your mRNA vaccines and therapies to the clinic.
BASE Clinical will produce mRNA and LNP batches, along with analytical services and quality documentation, for clinical trials.
These manufacturing services are supported by experienced process development, scale-up capabilities, and seamless technology transfer into our production facility.
We ensure the successful delivery of mRNA and LNP batches for early-stage clinical trials.
BASE Clinical will provide comprehensive analytical services to ensure the quality of our mRNA/LNP batches.
Our qualified and validated instruments and assays can accurately measure critical mRNA quality attributes, including identity, integrity, capping efficiency, impurities, and safety.
These capabilities are supported by an expert quality control team with extensive experience in mRNA/LNP analysis.
BASE Clinical is committed to providing mRNA and LNP batches at the highest-quality, purity and safety.
Our production undergoes rigorous quality control and is supported by phase-appropriate quality documentation and regulatory submission support.
Our robust Quality Management System (QMS) and team of quality experts ensure mRNA/LNP batches are manufactured at the highest level of quality, consistency and purity.